000169858 001__ 169858
000169858 005__ 20240229133657.0
000169858 0247_ $$2doi$$a10.1016/j.semcancer.2021.06.008
000169858 0247_ $$2pmid$$apmid:34116162
000169858 0247_ $$2ISSN$$a1044-579X
000169858 0247_ $$2ISSN$$a1096-3650
000169858 0247_ $$2altmetric$$aaltmetric:107540831
000169858 037__ $$aDKFZ-2021-01592
000169858 041__ $$aEnglish
000169858 082__ $$a610
000169858 1001_ $$0P:(DE-He78)261d2b84aded878003e6e35d18113831$$aBlattner-Johnson, Mirjam$$b0$$eFirst author$$udkfz
000169858 245__ $$aPrecision medicine in pediatric solid cancers.
000169858 260__ $$aLondon$$bAcademic Press$$c2022
000169858 3367_ $$2DRIVER$$aarticle
000169858 3367_ $$2DataCite$$aOutput Types/Journal article
000169858 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1656495576_7333$$xReview Article
000169858 3367_ $$2BibTeX$$aARTICLE
000169858 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169858 3367_ $$00$$2EndNote$$aJournal Article
000169858 500__ $$a#EA:B360#LA:B360# / 2022 Sep;84:214-227
000169858 520__ $$aDespite huge advances in the diagnosis and treatment of pediatric cancers over the past several decades, it remains one of the leading causes of death during childhood in developed countries. The development of new targeted treatments for these diseases has been hampered by two major factors. First, the extremely heterogeneous nature of the types of tumors encountered in this age group, and their fundamental differences from common adult carcinomas, has made it hard to truly get a handle on the complexities of the underlying biology driving tumor growth. Second, a reluctance of the pharmaceutical industry to develop products or trials for this population due to the relatively small size of the 'market', and a too-easy mechanism of obtaining waivers for pediatric development of adult oncology drugs based on disease type rather than mechanism of action, led to significant difficulties in getting access to new drugs. Thankfully, the field has now started to change, both scientifically and from a regulatory perspective, in order to address some of these challenges. In this review, we will examine some of the recent insights into molecular features which make pediatric tumors so unique and how these might represent therapeutic targets; highlight ongoing international initiatives for providing comprehensive, personalized genomic profiling of childhood tumors in a clinically-relevant timeframe, and look briefly at where the field of pediatric precision oncology may be heading in future.
000169858 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000169858 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169858 650_7 $$2Other$$aGenomics
000169858 650_7 $$2Other$$aPediatric cancer
000169858 650_7 $$2Other$$aPrecision medicine
000169858 650_7 $$2Other$$aTargeted therapy
000169858 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b1$$udkfz
000169858 7001_ $$0P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aPfaff, Elke$$b2$$eLast author$$udkfz
000169858 773__ $$0PERI:(DE-600)1471735-9$$a10.1016/j.semcancer.2021.06.008$$gp. S1044579X21001784$$p214-227$$tSeminars in cancer biology$$v84$$x1044-579X$$y2022
000169858 909CO $$ooai:inrepo02.dkfz.de:169858$$pVDB
000169858 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)261d2b84aded878003e6e35d18113831$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169858 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169858 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169858 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000169858 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000169858 9141_ $$y2021
000169858 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000169858 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000169858 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-08$$wger
000169858 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSEMIN CANCER BIOL : 2021$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2022-11-08
000169858 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bSEMIN CANCER BIOL : 2021$$d2022-11-08
000169858 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x0
000169858 980__ $$ajournal
000169858 980__ $$aVDB
000169858 980__ $$aI:(DE-He78)B360-20160331
000169858 980__ $$aUNRESTRICTED